ArticleFrontiers in oncology2025
Development and validation of a predictive model for severe radiation-induced esophagitis in lung cancer patients undergoing moderate hypofractionated radiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Moderate hypofractionated radiotherapy (MHRT) is an important treatment modality for lung cancer, offering shorter courses and improved local control, yet it also markedly increases the risk of severe radiation-induced esophagitis (RIE; grade ≥3). Severe RIE compromises quality of life and adherence to therapy and may necessitate interruption of radiotherapy. This study aimed to develop a prediction model based on clinical and dosimetric factors to identify high-risk patients receiving MHRT and to facilitate individualized treatment strategies. Methods: Lung cancer patients receiving moderate hypofractionated radiotherapy were included, with the endpoint defined as grade ≥3 radiation-induced esophagitis. Baseline characteristics were summarized using non-missing data only. During model development, in each outer bootstrap training set, candidate variables underwent single-rule imputation (median for continuous variables, mode for categorical variables) and standardization, followed by variable selection via elastic-net regression and model building with Firth-penalized logistic regression; the outcome itself was not imputed. Fully nested bootstrap validation (B=1000) was performed to assess internal robustness, with optimism-corrected performance metrics and 95% confidence intervals reported. Discrimination was evaluated using ROC curves and AUC, calibration by calibration plots and the Hosmer-Lemeshow test, and clinical utility through decision curve analysis (DCA). The optimal threshold was determined by the Youden index, with the corresponding confusion matrix presented. Finally, a nomogram was constructed to facilitate clinical visualization and application. Results: A total of 105 patients were included; the incidence of grade ≥3 RIE was 16.2% (17/105). Five predictors entered the final model via elastic-net selection: mean gross tumor volume (mean GTV), V5, D2cc, circumferential 2.6-Gy irradiated length, and circumferential 3.0-Gy irradiated length. The Firth-penalized logistic model showed good apparent performance: AUC=0.771, Brier score = 0.114, calibration slope = 1.16, and calibration intercept = 0.13. After optimism correction by fully nested bootstrap (B=1,000), discrimination decreased to AUC=0.608 (95% CI, 0.464-0.761) with a corresponding Brier score of 0.176 (95% CI, 0.114-0.247). The Hosmer-Lemeshow test yielded χ² = 7.84, p = 0.449, indicating acceptable overall fit. The Youden-index-derived optimal cutoff was 0.130, stratifying patients into high-risk (predicted probability ≥ 0.13) and lower-risk (< 0.13) groups. DCA demonstrated positive net benefit over "treat-all" and "treat-none" strategies across threshold probabilities of 0-0.8. Optimism-corrected calibration parameters were unstable, likely reflecting the limited number of events; these results should be interpreted with caution. Conclusion: Using elastic-net feature selection and Firth logistic regression, we developed a model to predict severe (grade ≥3) RIE in lung cancer patients undergoing MHRT. The model exhibited moderate discriminatory ability with generally acceptable calibration, enables risk stratification and identification of high-risk patients, and is presented as a nomogram to support clinical application. It holds promise for guiding individualized radiotherapy decisions and the prevention of treatment-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.